Treace John T. bought 50,000 shares of TREACE MEDICAL CONCEPTS, INC. at $3.56 for $178k on Jun 1, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Chief Executive Officer
Chief Executive Officer
Filed Jun 1, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$177,915Shares × reported price
Shares traded
50,000Common Stock
Price per share
$3.56Reported price. Read footnotes for ranges.
% of reported position traded
0.69%This security and ownership context
Holdings after
7,323,833Direct
Trade date
Jun 1, 2026Buy
Filed
Jun 1, 2026, 4:38 PM ET0-day reporting delay
Accession
0001193125-26-251587Code P · Transaction 387945
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 7,273,833 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

TMCI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TMCI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −48%1w ago −23%1d ago −3.9%
Returns since7d −1.9%30d +18%90d +29%180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.5100 to $3.6000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2: Includes 542,784 restricted stock units. F3: The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee. F4: The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.